Optimal use of blood thinners for venous clots in people with cirrhosis
Official title: Optimal prescribing of oral anticoagulants in patients with venous thromboembolism and cirrhosis
Funded at Brigham and Women's Hospital · NIH-11427117 · Data updated 2026-11-12
This grant hopes to figure out the safest and most effective way to use oral anticoagulants for adults with cirrhosis who develop venous clots.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 15, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $894,718 |
| NIH project number | 1R01HL187467-01 |
| Project ID | NIH-11427117 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with cirrhosis who have or are at risk for venous thromboembolism and are candidates for oral anticoagulation.
✕Less likely to help
Patients without cirrhosis or those not requiring anticoagulation may not benefit from this specific research.
What this research studies
Cirrhosis raises the risk of blood clots and complicates treatment because bleeding risks are higher. The project will gather and analyze data to understand which oral anticoagulants work best and are safest for these patients. By focusing on real-world outcomes and cirrhosis-specific factors, it aims to fill gaps left by prior trials that excluded this group. The goal is to guide clinicians in making better, personalized treatment choices for patients with cirrhosis and VTE.
Why it matters
Potential benefit: Patients with cirrhosis and VTE could receive more effective, safer anticoagulation tailored to their liver condition.
How similar studies have gone: Prior studies in this area are limited and often underpowered for cirrhosis-specific questions, making this work particularly novel.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Lin, Joshua K — Brigham and Women's Hospital
- Study coordinator: Lin, Joshua K
Related research
Other NIH-funded projects on the same topics.
-
Statins to Prevent Cancer-Associated Blood Clots in Cancer Patients
A large study will test whether taking rosuvastatin every day for a year can lower the chance of dangerous blood clots in people with cancer, without raising the risk of bleeding.
-
PET/CT imaging to detect chemotherapy-related vascular harm in young cancer patients
A non-invasive PET/CT scan method using standard care imaging is being tested to identify which pediatric and young adult cancer patients are at higher risk of blood clots from chemotherapy.
-
Statins to Prevent Cancer-Associated Blood Clots in Cancer Patients
A large clinical trial will test whether taking rosuvastatin daily for a year helps prevent dangerous blood clots in people with newly diagnosed or relapsed cancer who aren’t already getting anticoagulants.
-
BCOR's role in blood clot risk and liver genetics
A Johns Hopkins-led study is exploring how a human gene, BCOR, may control liver-produced clotting factors to influence venous blood clots.
-
Personalized risk-prediction for hospital-acquired blood clots in adults
A real-time risk model helps doctors identify adults in the hospital who are at higher risk of developing blood clots so they can prevent them safely.
-
Genomic and Proteomic Markers for Recurrent Venous Thromboembolism
Researchers are studying genetic and protein clues to predict who will have another blood clot after an initial VTE event, so doctors can tailor safer, more effective care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.